Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients

NCT00985036 | Withdrawn DMC

• 1 other identifier: MGH-VEGF-1
• Study Type: observational
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

Objectives: This study is looking at the level of vascular endothelial growth factor (VEGF) circulating in the blood stream of patients diagnosed with either a meningioma or a glioma. The questions that will be addressed include:

1. 1.Can VEGF level alert us to tumor progression or recurrence before MRI changes occur?
2. 2.Is the VEGF level an indicator of the response to treatment?
3. 3.Does the VEGF level correlate with tumor histology and behavior?
4. 4.Is there a relationship between VEGF level and outcome?

Conditions

Glioma; Meningioma

Keywords

glioma; meningioma; VEGF

Outcome Measures

Primary Outcomes (1)

• Determine if VEGF levels correlate with tumor progression or recurrence

  every one to three months

Secondary Outcomes (3)

• Determine if the VEGF level is an indicator of the response to treatment.

  Every one to three months

• Determine if the VEGF level correlates with tumor histology and behavior.

  Every one to three months

• Determine if there is a relationship between VEGF level and outcome.

  Every one to three months

Study Arms (2)

Glioma

patients who are diagnosed with and are being treated for glioma

Procedure: Blood test

meningioma

patients who are diagnosed with and are being treated for meningioma

Procedure: Blood test

Interventions

Blood test PROCEDURE

an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test

Glioma; meningioma

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients presenting to Marquette General Hospital with a probable or confirmed diagnosis of meningioma or glioma

You may qualify if:

• any patient presenting with glioma or meningioma

You may not qualify if:

• a different type of brain tumor

Sponsors & Collaborators

• Marquette General Health System: lead
• Upper Michigan Brain Tumor Center: collaborator

Study Sites (1)

Marquette General Hospital

Marquette, Michigan, 49855, United States

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

serum

MeSH Terms

Conditions

Glioma; Meningioma

Interventions

Hematologic Tests

Condition Hierarchy (Ancestors)

Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Neoplasms, Vascular Tissue; Meningeal Neoplasms; Central Nervous System Neoplasms; Nervous System Neoplasms; Neoplasms by Site; Nervous System Diseases

Intervention Hierarchy (Ancestors)

Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Investigative Techniques

Study Officials

• Richard A Rovin, MD, FACS

  Upper Michigan Brain Tumor Center

  PRINCIPAL INVESTIGATOR

• Robert J Winn, PhD

  Northern Michigan University

  PRINCIPAL INVESTIGATOR

• Suresh Nukala, MD

  Marquette General Health Systems

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Neurosurgeon

Study Record Dates

• First Submitted: September 25, 2009
• First Posted: September 28, 2009
• Study Start: September 1, 2009
• Primary Completion: September 1, 2011
• Study Completion: January 1, 2012
• Last Updated: April 24, 2012

Record last verified: 2012-04

Locations

US (1)